(CRSP) CRISPR Therapeutics AG BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRSP) CRISPR Therapeutics AG Complete Analysis Pack
Actionable Strategy Starts Here
This CRISPR Therapeutics AG BCG Matrix helps you see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs, supporting strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
Casgevy, first approved CRISPR medicine
Casgevy, approved by the FDA in December 2023, is CRISPR Therapeutics AG’s first marketed product and a clear leader in gene editing. It is co-commercialized with Vertex and carries a U.S. list price of about $2.2 million per patient, showing strong pricing power in a high-growth niche. That makes it the main Star in the BCG matrix heading into end-2025.
Sickle cell disease label
Casgevy has a clear U.S. and ex-U.S. path in severe sickle cell disease, where more than 100,000 people in the U.S. and about 8 million globally live with the disorder. Only a fraction are treated today, so each new payer deal and treatment center expands the pool. That high unmet need keeps this label in Star territory.
Transfusion-dependent beta-thalassemia label
Transfusion-dependent beta-thalassemia is the second approved label for CRISPR Therapeutics AG’s exa-cel, after sickle cell disease, and it cuts single-indication risk. With two U.S. orphan-style approvals, the asset can address two severe hemoglobin disorders that together affect tens of thousands of treated patients in major markets. That wider reach raises the long-term revenue ceiling and keeps the product in a high-growth BCG position.
Ex vivo hematopoietic stem-cell editing platform
CRISPR Therapeutics AG’s ex vivo hematopoietic stem-cell editing platform is Star-like because one approved therapy, Casgevy, has already validated the science and manufacturing path. That commercial proof matters: it raises confidence for future blood-disease programs and helps de-risk the platform. In a gene-editing market that is still early but expanding, proven platform value is a key advantage.
- One approved therapy already validates the platform.
- Commercial proof supports future blood-disease launches.
- Platform leadership fits a Star in BCG terms.
Vertex co-commercialized launch
Vertex co-commercializes Casgevy with CRISPR Therapeutics AG, giving the therapy Vertex's global sales force, payer access, and launch execution. Casgevy reached first U.S. approvals in 2023 and, by 2024, had broadened into multiple markets, which cuts go-to-market risk while demand is still early. That scale matters if manufacturing slots and reimbursement keep opening.
- Vertex lowers launch risk.
- Better payer access supports uptake.
- Global scale can speed adoption.
Casgevy Could Drive CRISPR’s Next Big Growth Wave
Casgevy is CRISPR Therapeutics AG’s Star asset: FDA-approved in December 2023, co-marketed with Vertex, and priced at about $2.2 million per patient in the U.S. With severe sickle cell disease affecting over 100,000 people in the U.S. and about 8 million globally, adoption still has room to run.
| Star driver | Key data |
|---|---|
| Lead product | Casgevy |
| U.S. list price | About $2.2 million |
| Sickle cell burden | >100,000 U.S.; ~8 million global |
What is included in the product
Detailed Word Document
CRISPR Therapeutics’ BCG Matrix maps its gene-editing pipeline into invest, hold, or divest priorities amid fast-changing biotech trends.
Editable Excel File
One-page BCG matrix for CRISPR Therapeutics AG, quickly clarifying portfolio pain points and priorities for action
Reference Sources
Lists the key CRISPR Therapeutics sources so claims are traceable, credible, and easy to use in decisions.
Cash Cows
Casgevy commercial sales stream
Casgevy is already commercial, so it is no longer pure R&D. At about $2.2 million per U.S. patient for sickle cell disease, even modest treatment volume can build meaningful recurring cash as launch sites, reimbursement, and patient flow normalize. By end-2025, it is CRISPR Therapeutics AG’s closest thing to a Cash Cow.
Vertex profit-sharing economics
Vertex profit-sharing makes Casgevy a cash cow candidate because CRISPR can monetize an approved therapy without funding a full sales force. In 2025, the asset had turned from pure R&D risk into shared commercial economics, which lowers burn and raises cash conversion. That is much closer to mature pharma economics than an early biotech bet.
2 approved hemoglobinopathy indications
CRISPR Therapeutics AG now has 2 approved hemoglobinopathy indications: sickle cell disease and transfusion-dependent beta-thalassemia. That makes Casgevy a repeatable commercial platform, not a one-off program, because each sale uses the same core edit-and-infuse model. Label expansion and post-approval support are far cheaper than funding a new discovery path for every patient segment.
Treatment-center network buildout
CRISPR Therapeutics AG’s treatment-center network is a cash cow setup because cell therapy launch economics hinge on qualified sites, not just product demand. Casgevy’s U.S. list price is about $2.2 million per patient, so once a center is trained and certified, the cost to add each extra patient usually falls fast, lifting cash conversion over time.
Front-loaded site buildout, lower marginal patient cost
Network depth improves access and throughput
High-ticket therapy supports durable cash generation
More centers can widen the addressable market
Manufacturing and supply chain for exa-cel
exa-cel’s ex vivo process is now a repeatable GMP workflow, not a one-off science project. As Casgevy sales ramp, fixed plant and release costs can be spread across more patient batches, which should improve unit economics. That makes the manufacturing base Cash Cow-like even while revenue is still early.
- Repeatable autologous batch flow
- Scale lifts throughput
- Fixed costs dilute with volume
- Cash Cow traits before peak sales
Casgevy Becomes CRISPR’s Closest Cash Cow in 2025/26
Casgevy is CRISPR Therapeutics AG’s closest Cash Cow in 2025/2026: two approved hemoglobinopathy uses, a $2.2 million U.S. list price, and shared Vertex economics. As treatment sites and reimbursement settle, each added patient should cost less to serve, so cash conversion can rise. The manufacturing base is now repeatable, not experimental.
| Metric | Value |
|---|---|
| Approved indications | 2 |
| U.S. list price | ~$2.2M |
| Economics | Vertex profit share |
What You See Is What You Get
CRISPR Therapeutics AG Reference Sources
You're previewing the exact CRISPR Therapeutics AG BCG Matrix document you'll receive after purchase. No demo pages, no placeholders—just the full, professionally formatted report. Once purchased, it’s delivered instantly for download and ready to use for analysis, presentations, or planning.
Dogs
CTX110, 0 approvals
CTX110 had 0 approvals by end-2025 and stayed clinical only, so CRISPR Therapeutics AG had no commercial share in the CD19 space. The market is already led by approved CD19 CAR-Ts like Yescarta, Kymriah, Tecartus, and Breyanzi, with 2025 sales in the billions across the class. Without clear differentiation, CTX110 still fits the Dog bucket.
CTX120, 0 approvals
CTX120 has 0 approvals and is still uncommercialized, so it remains a clear Dog in CRISPR Therapeutics AG’s BCG matrix. In multiple myeloma, BCMA rivals already have approvals, including CAR-Ts and bispecifics, which makes share capture hard. Until late-stage data proves stronger efficacy and safety, CTX120 is a low-share asset.
CTX130, 0 approvals
CTX130 is CRISPR Therapeutics AG's CD70 cell therapy for solid tumors and blood cancers, but it still has 0 approvals and early-stage risk. Solid-tumor cell therapy remains a tough market, with no proven CRISPR commercial position. That keeps CTX130 in dog territory for now.
Oncology CAR-T portfolio, 0 marketed products
CRISPR Therapeutics had no marketed oncology CAR-T product by end-2025, so the line still burns R&D cash while peers like Gilead and Bristol Myers already sell in market. With zero oncology sales and no commercial share, this basket fits BCG "dog" status until a late-stage win changes the curve.
In 2025, CRISPR's R&D spend stayed near $800 million, so this segment remains a cash drain, not a cash engine.
- Zero marketed oncology products
- 2025 R&D near $800 million
- No sales, no share, dog profile
Non-Casgevy commercial base, 0 revenue brands
CRISPR Therapeutics AG still fits a Dog profile outside Casgevy: as of FY2025, it had only one marketed brand, so the rest of the pipeline produced no commercial revenue. That leaves non-core programs as cash users, not cash generators, which is classic thin-base risk. The key issue is concentration, not just growth.
- FY2025: only Casgevy was marketed.
- Non-Casgevy brands generated $0 sales.
- Pipeline spend still weighed on cash flow.
CRISPR’s Oncology Dogs Still Burn Cash, With No Sales Yet
CRISPR Therapeutics AG’s Dog assets stayed low-share and cash-heavy in FY2025: CTX110, CTX120, and CTX130 had 0 approvals, 0 sales, and no marketed oncology presence. With about $800 million in 2025 R&D spend and only Casgevy sold, these programs still drain capital. Until one program proves late-stage wins and market pull, they remain Dogs.
| Asset | FY2025 status | BCG view |
|---|---|---|
| CTX110 | 0 approvals, 0 sales | Dog |
| CTX120/CTX130 | 0 approvals, early stage | Dog |
Question Marks
VCTX210, type 1 diabetes
VCTX210 sits in Question Marks because it targets type 1 diabetes, a huge unmet need, but CRISPR Therapeutics AG has no commercial share yet. The global type 1 diabetes burden is already in the millions, so the addressable market is large if the stem cell and immune-evasive biology works. Heavy R&D spend could lift it into a Star, but only after clinical proof and scale-up.
In vivo liver editing
CRISPR Therapeutics AG’s in vivo liver editing is still a Question Mark: the liver is a top first target for CRISPR because IV delivery is practical, but CRISPR Therapeutics AG has zero commercial share here today. The field is expanding fast, with in vivo gene-editing rivals advancing liver programs in 2025-2026, but CRISPR Therapeutics AG has yet to turn this into sales. That makes the asset high-upside, but still unproven.
In vivo lung editing
In vivo lung editing is a Question Mark for CRISPR Therapeutics AG: the market is huge, with COPD causing about 3.5 million deaths a year and cystic fibrosis affecting roughly 105,000 people worldwide, but delivery to the lung is still technically hard and pre-commercial. As of FY2025, CRISPR Therapeutics AG had no established lung-editing sales, so share is still near zero. The upside is strong, but it needs proof of clinical delivery and scale.
In vivo muscle editing
In vivo muscle editing is a high-potential Question Mark for CRISPR Therapeutics AG because muscle diseases are a very large unmet need, but delivery still limits reach and market share is near zero. The company is still in development here, while its 2025 revenue was driven by other programs, led by CASGEVY at $55 million in Q1 2025. That gap makes this bet early, risky, and potentially big.
- Large long-term disease pool
- Delivery remains the key bottleneck
- Minimal current market share
- High upside, high R&D risk
In vivo CNS editing
In vivo CNS editing sits in CRISPR Therapeutics AG’s Question Marks: the rare-disease upside is large, but delivery across the blood-brain barrier keeps technical risk high and the path to revenue early. This is a high-growth, low-share, high-uncertainty bucket, so capital needs can rise before any proof of scale. For now, it is more option value than earnings engine.
Large unmet need, but hard CNS delivery
Early commercial path, no clear scale yet
High growth potential, low current share
CRISPR’s High-Risk Question Marks: Big Upside, Early Proof Needed
CRISPR Therapeutics AG’s Question Marks are early, high-upside bets with near-zero share and heavy R&D risk. VCTX210 targets a type 1 diabetes market of millions, while in vivo liver, lung, muscle, and CNS editing all face delivery bottlenecks before revenue. CASGEVY brought $55 million in Q1 2025, but these programs still need clinical proof.
| Area | Status | Key data |
|---|---|---|
| VCTX210 | Question Mark | Type 1 diabetes; no share |
| Liver editing | Question Mark | IV feasible; no sales |
| Lung editing | Question Mark | COPD 3.5m deaths; no sales |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.